Published in Psychopharmacology (Berl) on March 01, 2014
Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br J Pharmacol (2017) 0.79
Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents. J Neuroinflammation (2016) 0.77
Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci (2016) 0.75
Antroquinonol Lowers Brain Amyloid-β Levels and Improves Spatial Learning and Memory in a Transgenic Mouse Model of Alzheimer's Disease. Sci Rep (2015) 0.75
Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model. Neuropsychopharmacology (2017) 0.75
Cannabidiol Regulation of Learned Fear: Implications for Treating Anxiety-Related Disorders. Front Pharmacol (2016) 0.75
In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease. Front Pharmacol (2017) 0.75
The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry (1982) 10.83
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA (2004) 6.74
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav (2004) 5.15
Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng (2001) 4.64
Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron (1997) 4.49
Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain (2013) 3.87
Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome. Nat Neurosci (2007) 3.74
Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci (2008) 3.19
The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev (2007) 2.68
Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A (1998) 2.48
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009) 2.32
The relation between fear induced by novel stimulation and exploratory behavior. J Comp Physiol Psychol (1955) 2.13
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol (2007) 1.85
Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav (2007) 1.72
ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem (2010) 1.64
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr (2008) 1.61
Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging (2005) 1.60
Activation of microglia by secreted amyloid precursor protein evokes release of glutamate by cystine exchange and attenuates synaptic function. J Neurochem (2001) 1.56
Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacol Ther (2011) 1.45
Anxiogenic-like effects of chronic cannabidiol administration in rats. Psychopharmacology (Berl) (2011) 1.44
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res (2008) 1.32
GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS One (2008) 1.26
Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. J Neurochem (2004) 1.20
Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) (2008) 1.19
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci (2012) 1.15
Thy1-hAPP(Lond/Swe+) mouse model of Alzheimer's disease displays broad behavioral deficits in sensorimotor, cognitive and social function. Brain Behav (2012) 1.15
APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol Aging (2004) 1.15
Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J Alzheimers Dis (2004) 1.15
Pharmacological characterization of cannabinoids in the elevated plus maze. J Pharmacol Exp Ther (1990) 1.13
Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neurosci Ther (2009) 1.12
Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: characteristics and treatment. Neurol Clin (2000) 1.12
Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) (1990) 1.11
Behavioural profile of a new mouse model for NPY deficiency. Eur J Neurosci (2008) 1.10
Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress. Free Radic Biol Med (2011) 1.05
A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol (2009) 1.03
Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry (2006) 1.03
The relation between fear and exploratory behavior. J Comp Physiol Psychol (1955) 1.03
Cognition in transmembrane domain neuregulin 1 mutant mice. Neuroscience (2010) 1.01
Glutamate and other CSF amino acids in Alzheimer's disease. Am J Psychiatry (1992) 1.00
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) (2011) 1.00
Palmitoylethanolamide counteracts reactive astrogliosis induced by β-amyloid peptide. J Cell Mol Med (2011) 0.99
The marijuana component cannabidiol inhibits beta-amyloid-induced tau protein hyperphosphorylation through Wnt/beta-catenin pathway rescue in PC12 cells. J Mol Med (Berl) (2005) 0.99
The effect of ageing on neurogenesis and oxidative stress in the APP(swe)/PS1(deltaE9) mouse model of Alzheimer's disease. Brain Res (2012) 0.99
Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol (2007) 0.98
Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease. Alzheimers Res Ther (2013) 0.97
Endocannabinoids and neurodegenerative diseases. Pharmacol Res (2007) 0.97
Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One (2011) 0.97
Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int (2010) 0.97
Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol (2011) 0.96
Exploratory activity, anxiety, and motor coordination in bigenic APPswe + PS1/DeltaE9 mice. Neurosci Lett (2004) 0.96
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis. Curr Med Res Opin (2010) 0.93
Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis. Cell Commun Signal (2010) 0.92
Differential effects of the N-methyl-d-aspartate receptor antagonist MK-801 on different stages of object recognition memory in mice. Neuroscience (2007) 0.92
Cannabinoids for the treatment of dementia. Cochrane Database Syst Rev (2009) 0.91
Inflammation and aging: can endocannabinoids help? Biomed Pharmacother (2008) 0.89
The endocannabinoid system and Alzheimer's disease. Mol Neurobiol (2007) 0.88
The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol (2013) 0.87
Functional cholinergic damage develops with amyloid accumulation in young adult APPswe/PS1dE9 transgenic mice. Neurobiol Dis (2010) 0.87
Anomalies in social behaviors and exploratory activities in an APPswe/PS1 mouse model of Alzheimer's disease. Physiol Behav (2011) 0.86
Cognition in female transmembrane domain neuregulin 1 mutant mice. Behav Brain Res (2011) 0.84
Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. PLoS One (2012) 0.84
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.84
Cognitive phenotyping of amyloid precursor protein transgenic J20 mice. Behav Brain Res (2011) 0.83
Targeting the endocannabinoid system in Alzheimer's disease. J Alzheimers Dis (2008) 0.81
Novel behavioural characteristics of the APP(Swe)/PS1ΔE9 transgenic mouse model of Alzheimer's disease. Behav Brain Res (2013) 0.81
Role of Abca7 in mouse behaviours relevant to neurodegenerative diseases. PLoS One (2012) 0.80
Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. Learn Mem (2001) 0.80
In vivo hippocampal microdialysis reveals impairment of NMDA receptor-cGMP signaling in APP(SW) and APP(SW)/PS1(L166P) Alzheimer's transgenic mice. Neurochem Int (2012) 0.79
Distribution patterns of cannabinoid CB1 receptors in the hippocampus of APPswe/PS1ΔE9 double transgenic mice. Brain Res (2010) 0.77
The therapeutic potential of the endocannabinoid system for Alzheimer's disease. Expert Opin Ther Targets (2012) 0.76
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain (2014) 2.74
Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl) (2011) 1.84
Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J Neurochem (2007) 1.51
Characterization of the kynurenine pathway in human neurons. J Neurosci (2007) 1.44
Quantitation of ATP-binding cassette subfamily-A transporter gene expression in primary human brain cells. Neuroreport (2006) 1.26
ATP-binding cassette transporter A7 regulates processing of amyloid precursor protein in vitro. J Neurochem (2008) 1.20
Deletion of Abca7 increases cerebral amyloid-β accumulation in the J20 mouse model of Alzheimer's disease. J Neurosci (2013) 1.14
Attenuation of the lysosomal death pathway by lysosomal cholesterol accumulation. Am J Pathol (2011) 1.10
Role of ABCG1 and ABCA1 in regulation of neuronal cholesterol efflux to apolipoprotein E discs and suppression of amyloid-beta peptide generation. J Biol Chem (2006) 1.08
Glycosphingolipid accumulation inhibits cholesterol efflux via the ABCA1/apolipoprotein A-I pathway: 1-phenyl-2-decanoylamino-3-morpholino-1-propanol is a novel cholesterol efflux accelerator. J Biol Chem (2005) 1.07
Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem Pharmacol (2006) 1.07
A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol (2009) 1.03
Y1 receptors are critical for the proliferation of adult mouse precursor cells in the olfactory neuroepithelium. J Neurochem (2007) 0.97
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
Behavioral profile of a heterozygous mutant mouse model for EGF-like domain neuregulin 1. Behav Neurosci (2008) 0.96
Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. Int J Neuropsychopharmacol (2009) 0.95
Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. J Lipid Res (2007) 0.93
Neuropeptide Y (NPY) cleaving enzymes: structural and functional homologues of dipeptidyl peptidase 4. Peptides (2007) 0.93
Apolipoproteins in the brain: implications for neurological and psychiatric disorders. Clin Lipidol (2010) 0.93
Dolichol is the major lipid component of human substantia nigra neuromelanin. J Neurochem (2005) 0.93
Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiol Aging (2009) 0.92
An improved high-throughput lipid extraction method for the analysis of human brain lipids. Lipids (2013) 0.92
Selective reduction of hydroperoxyeicosatetraenoic acids to their hydroxy derivatives by apolipoprotein D: implications for lipid antioxidant activity and Alzheimer's disease. Biochem J (2012) 0.91
Impact of 27-hydroxycholesterol on amyloid-beta peptide production and ATP-binding cassette transporter expression in primary human neurons. J Alzheimers Dis (2009) 0.91
A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats. Neurobiol Dis (2009) 0.89
The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. Int J Neuropsychopharmacol (2010) 0.88
Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice. J Lipid Res (2008) 0.88
Sensitivity to lysosome-dependent cell death is directly regulated by lysosomal cholesterol content. PLoS One (2012) 0.88
The kynurenine pathway and inflammation in amyotrophic lateral sclerosis. Neurotox Res (2009) 0.88
Single high dose treatment with methotrexate causes long-lasting cognitive dysfunction in laboratory rodents. Pharmacol Biochem Behav (2010) 0.87
Increased levels of serotonin 2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. Schizophr Res (2007) 0.87
Obesity and the associated mediators leptin, estrogen and IGF-I enhance the cell proliferation and early tumorigenesis of breast cancer cells. Nutr Cancer (2009) 0.86
HPLC analysis of discrete haptoglobin isoform N-linked oligosaccharides following 2D-PAGE isolation. Biochem Biophys Res Commun (2006) 0.86
Phosphorylation of apolipoprotein-E at an atypical protein kinase CK2 PSD/E site in vitro. Biochemistry (2005) 0.86
Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains. Biochem J (2011) 0.86
Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. Acta Neuropathol Commun (2014) 0.86
Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. Int J Neuropsychopharmacol (2012) 0.85
Modulation of brain metabolism by very low concentrations of the commonly used drug delivery vehicle dimethyl sulfoxide (DMSO). J Neurosci Res (2008) 0.85
A follow-up study: acute behavioural effects of Delta(9)-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice. Psychopharmacology (Berl) (2010) 0.85
Distinct neurobehavioural effects of cannabidiol in transmembrane domain neuregulin 1 mutant mice. PLoS One (2012) 0.84
Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice. Front Cell Neurosci (2013) 0.84
Regulation of alpha-synuclein expression by liver X receptor ligands in vitro. Neuroreport (2008) 0.84
Cognition in female transmembrane domain neuregulin 1 mutant mice. Behav Brain Res (2011) 0.84
Apolipoprotein-D expression is increased during development and maturation of the human prefrontal cortex. J Neurochem (2009) 0.83
Cognitive phenotyping of amyloid precursor protein transgenic J20 mice. Behav Brain Res (2011) 0.83
Effects of chronic risperidone treatment on the striatal protein profiles in rats. Brain Res (2006) 0.83
Increased expression of the lysosomal cholesterol transporter NPC1 in Alzheimer's disease. Biochim Biophys Acta (2010) 0.83
Is seladin-1 really a selective Alzheimer's disease indicator? J Alzheimers Dis (2012) 0.82
Alanine metabolism, transport, and cycling in the brain. J Neurochem (2007) 0.82
The response of neuregulin 1 mutant mice to acute restraint stress. Neurosci Lett (2012) 0.82
Molecular dynamics analysis of apolipoprotein-D-lipid hydroperoxide interactions: mechanism for selective oxidation of Met-93. PLoS One (2012) 0.82
Y2Y4 receptor double knockout protects against obesity due to a high-fat diet or Y1 receptor deficiency in mice. Diabetes (2006) 0.82
Analysis of subcellular [57Co] cobalamin distribution in SH-SY5Y neurons and brain tissue. J Neurosci Methods (2013) 0.82
Induction of fibroblast apolipoprotein E expression during apoptosis, starvation-induced growth arrest and mitosis. Biochem J (2004) 0.81
Novel behavioural characteristics of the APP(Swe)/PS1ΔE9 transgenic mouse model of Alzheimer's disease. Behav Brain Res (2013) 0.81
Dynorphin knockout reduces fat mass and increases weight loss during fasting in mice. Mol Endocrinol (2007) 0.81
Apoptosis induces neuronal apolipoprotein-E synthesis and localization in apoptotic bodies. Neurosci Lett (2007) 0.81
Heterogeneous expression of apolipoprotein-E by human macrophages. Immunology (2004) 0.81
Increased ATP-binding cassette transporter A1 expression in Alzheimer's disease hippocampal neurons. J Alzheimers Dis (2010) 0.81
Srp20 regulates TrkB pre-mRNA splicing to generate TrkB-Shc transcripts with implications for Alzheimer's disease. J Neurochem (2012) 0.81
Apolipoprotein-E forms dimers in human frontal cortex and hippocampus. BMC Neurosci (2010) 0.81
Role of Abca7 in mouse behaviours relevant to neurodegenerative diseases. PLoS One (2012) 0.80
Evidence that truncated TrkB isoform, TrkB-Shc can regulate phosphorylated TrkB protein levels. Biochem Biophys Res Commun (2012) 0.80
Lipids and Alzheimer's disease. Biochim Biophys Acta (2010) 0.79
Analysis of apolipoprotein E nuclear localization using green fluorescent protein and biotinylation approaches. Biochem J (2008) 0.79
Modulation of amyloid precursor protein processing by synthetic ceramide analogues. Biochim Biophys Acta (2010) 0.79
Myriocin-mediated up-regulation of hepatocyte apoA-I synthesis is associated with ERK inhibition. Clin Sci (Lond) (2010) 0.79
Age-related lysosomal dysfunction: an unrecognized roadblock for cobalamin trafficking? Cell Mol Life Sci (2011) 0.78
Increased apolipoprotein D dimer formation in Alzheimer's disease hippocampus is associated with lipid conjugated diene levels. J Alzheimers Dis (2013) 0.78
Altered ceramide acyl chain length and ceramide synthase gene expression in Parkinson’s disease. Mov Disord (2014) 0.78
Perturbation of neuronal cobalamin transport by lysosomal enzyme inhibition. Biosci Rep (2014) 0.77
Examining the preparation and ongoing support of adults to take their medications as prescribed in kidney transplantation. J Eval Clin Pract (2014) 0.77
Fine tuning therapeutic targeting of the sphingolipid biosynthetic pathway to treat atherosclerosis. Curr Vasc Pharmacol (2006) 0.76
Neuregulin 1 Prevents Phencyclidine-Induced Behavioral Impairments and Disruptions to GABAergic Signaling in Mice. Int J Neuropsychopharmacol (2015) 0.76
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology (2006) 0.76
The therapeutic potential of the endocannabinoid system for Alzheimer's disease. Expert Opin Ther Targets (2012) 0.76
Wild type and Tangier disease ABCA1 mutants modulate cellular amyloid-β production independent of cholesterol efflux activity. J Alzheimers Dis (2011) 0.76
Dissociation of ERK signalling inhibition from the anti-amyloidogenic action of synthetic ceramide analogues. Clin Sci (Lond) (2012) 0.75
The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease. Behav Pharmacol (2017) 0.75
Vascular pharmacotherapy and dementia. Curr Vasc Pharmacol (2010) 0.75
Macrophage apolipoprotein-E knockdown modulates caspase-3 activation without altering sensitivity to apoptosis. Biochim Biophys Acta (2007) 0.75